The AI data center must incur a monthly diesel generation cost of $15 million based on a 50MW inference facility to avoid delays in connecting to the power grid. According to analysis, the speed of power connection, along with GPU procurement, can determine the operational timeline of AI infrastructure. Neil Somani, founder of Eclipse, stated that utilizing a combination of rental diesel generators could allow the AI data center to bypass power grid connection bottlenecks within months. A facility of 50MW would require approximately 40 rental diesel generators, with a monthly rental fee of about $2 million, and an estimated monthly diesel consumption of around 2.5 million gallons, costing approximately $12.5 million. The cooling system cost is estimated at about $1 million. The hardware investment is projected to be around $1.9 billion, with monthly revenues potentially reaching about $180 million. The issue of power bottlenecks is a recurring topic in discussions about large-scale AI data centers, as the method of power procurement significantly impacts the cost structure. While the diesel generator method is presented as an option to expedite the operational timeline before grid connection, diesel costs account for the majority of the total monthly expenses. The debate over the cost burden of AI data centers and the power grid is also escalating into regional regulatory issues.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.

Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.














Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.